Our study in 21 pediatric cancer patients demonstrates that 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemotherapy. Immunity was stronger in children with solid tumors and during maintenance therapy compared to those with hematological malignancies or during intensive chemotherapy. Clinical Trials Registration. German Registry for Clinical Trials (DRKS00025254).

中文翻译：

---

接受癌症化疗的儿科患者对 3 剂冠状病毒病信使 RNA 疫苗 (COVID-19) 的纵向免疫反应

我们对 21 名儿童癌症患者的研究表明，在化疗期间，3 剂严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 信使 RNA 疫苗 (BioNTech/Pfizer) 在大多数患者中引发了体液免疫和细胞免疫。与患有血液恶性肿瘤或强化化疗期间的儿童相比，患有实体瘤和维持治疗期间的儿童的免疫力更强。临床试验注册。德国临床试验登记处 (DRKS00025254)。